Highmark GLP-1 Coverage & Prior-Authorization Guide (2026)

Highmark serves members across Delaware, New York, Pennsylvania, and West Virginia, and it publishes its GLP-1 anti-obesity prior-authorization criteria through named policy bulletins rather than a single master document. We pulled the governing Special Bulletin and provider-manual appeal rules directly on 2026-07-10 and quote them verbatim below. If your Highmark prior authorization for Wegovy, Saxenda, or Zepbound has been delayed or denied, this is the source-of-truth for every clause your prescriber can address.

The bottom line

• Highmark covers Wegovy, Saxenda, and plan-preferred Zepbound for chronic weight management only when the member's specific plan includes an anti-obesity pharmacy benefit, and only through strict prior authorization.
• Effective in late 2024 (09/01/2024 for fully-insured/ACA plans in Delaware, West Virginia, and New York; 10/01/2024 in Pennsylvania), Highmark tightened criteria dramatically: baseline BMI raised to ≥ 40 plus a metabolic or comorbidity requirement, step therapy through plan-preferred Zepbound, and a ≥ 7.5% weight-loss reauthorization gate.
• Diabetes GLP-1s — Ozempic and Mounjaro — are unaffected and remain covered under separate diabetes criteria.
• Many self-insured employer groups (ASO) exclude the anti-obesity benefit entirely, so a member can fail every clinical criterion check and still have no path to coverage because the benefit itself was never purchased by their employer.

What Highmark actually covers

The single biggest source of confusion in Highmark GLP-1 denials is not the clinical criteria — it's whether the anti-obesity pharmacy benefit exists on the member's plan at all. Highmark draws a hard line between two plan types, and the criteria below only apply to one of them.

• Fully-insured and ACA plans are subject to Highmark's revised anti-obesity policy. New-to-therapy members in Delaware and West Virginia moved to the tightened criteria 09/01/2024; New York also moved 09/01/2024; Pennsylvania moved 10/01/2024. Members with an existing prior authorization transition to the new criteria at reauthorization, after an advance notice letter (60 days in PA/DE/WV; 90 days in NY, following 2025 group renewal).
• Self-insured (ASO / employer-group) plans are not automatically impacted. Prior-authorization criteria for weight-loss medications on Highmark's commercial self-insured book were unchanged by the 2024 revision, and the anti-obesity benefit itself is optional per employer group — each ASO group separately elects the “Enhanced” policy (J-1388), the “Standard” policy (J-1389), or excludes the anti-obesity benefit entirely.
• Zepbound is the plan-preferred GLP-1. Saxenda and Wegovy require documented intolerance or a contraindication to Zepbound first — a step-therapy requirement most third-party explainers miss.
• Diabetes GLP-1s are carved out. Ozempic and Mounjaro, prescribed for type 2 diabetes, are governed by separate diabetes criteria and are not affected by any of the anti-obesity restrictions described here.
• Current governing policies for new users are J-1388 Anti-Obesity (Enhanced), effective 08/26/2025, and J-1389 (Standard). Policy J-0184 is a transition policy that applies only to established users until their existing prior authorization expires (in New York, until the plan renews) — after which J-1388 or J-1389 applies.
• January 2026 formulary update: orforglipron and the Wegovy oral tablet were added as target agents in both the Enhanced and Standard anti-obesity policies, “effective upon internal review” — Highmark has not published a firm effective date for this change.

Prior authorization criteria (Enhanced policy J-1388)

The Enhanced policy (J-1388) governs Saxenda, Wegovy, and Zepbound for fully-insured and ACA members whose plan carries the anti-obesity pharmacy benefit. Full adult criteria:

• Applies only to members whose plan includes the anti-obesity pharmacy benefit; Zepbound is plan-preferred — Saxenda and Wegovy require documented intolerance or contraindication to Zepbound first (step therapy).
• Age ≥ 18 (separate adolescent criteria apply for ages 12–17); use for chronic weight management, ICD-10 E66.0 or E66.3.
• Baseline BMI ≥ 40 kg/m² PLUS one of: (A) prediabetes (A1C 5.7–6.4%, fasting plasma glucose 100–125, or OGTT 140–199) AND triglycerides ≥ 150 mg/dL AND HDL < 40 (men) / < 50 (women); OR (B) at least two obesity-caused organ-dysfunction manifestations (e.g. obstructive sleep apnea, PCOS, hypertension, coronary artery disease, severe knee or hip osteoarthritis).
• Documentation of healthy dietary changes AND increased physical activity for at least 6 months prior to initiation, continued during therapy.
• Prescriber must attest the member does NOT have a type 2 diabetes diagnosis.
• The drug must not be used in combination with any other GLP-1 receptor agonist or GLP-1/GIP combination product.

Reauthorization and adolescent criteria:

1. Reauthorization / maintenance (≥ 7 months on therapy): documented and maintained ≥ 7.5% weight loss from baseline plus maintenance dosing (Wegovy 1.7/2.4 mg weekly; Zepbound 5/7.5/10/12.5/15 mg weekly; Saxenda 2.4/3 mg daily). Non-GLP-1 oral agents (Contrave, Qsymia, Xenical) use a lower baseline BMI ≥ 35 with a ≥ 5% reauthorization threshold instead.
2. Adolescent Saxenda/Wegovy: baseline BMI ≥ 36 kg/m² or ≥ 120% of the 95th percentile for age and sex; maintenance requires a BMI reduction of ≥ 3 percentile points.

Verbatim policy language

Highmark's own Special Bulletin language on the four points most prescribers get wrong:

“For Saxenda, Wegovy, and Zepbound for initiation and maintenance in adults, requiring age of 18 years or older, use for chronic weight management, baseline BMI ≥ 40 kg/m2, at least two weight-related comorbidities … attestation that the member does not have type 2 diabetes, that the agent will not be used with any other GLP-1 RA containing agent, and if the request is for Saxenda or Wegovy, intolerance/contraindication to plan-preferred Zepbound. Additionally for maintenance, weight loss of ≥ 7.5% from baseline and maintenance dosing.”

— Highmark Special Bulletin (Aug 30, 2024) — Revised Prescription Medication Policy for Weight Loss Medications; Anti-Obesity Fully-Insured Commercial & ACA policy, eff. 09/01/2024

“Prior authorization criteria for weight loss medications for Highmark's commercial self-insured members is not impacted.”

— Highmark Special Bulletin (Aug 30, 2024) — Revised Prescription Medication Policy for Weight Loss Medications

“This policy change also does not affect FDA-approved GLP-1s used in the treatment of type 2 diabetes.”

— Highmark Special Bulletin (Aug 30, 2024) — Revised Prescription Medication Policy for Weight Loss Medications

“A provider has 180 days from the date of the initial denial of coverage in which to file an appeal in all of Highmark's service areas in Delaware, New York, Pennsylvania, and West Virginia.”

— Highmark Provider Manual, Chapter 5 Unit 5: Denials, Adverse Benefit Determinations, Grievances, and Appeals

How to appeal a denial

Members or the treating provider may appeal an adverse determination within 180 days of the initial denial, across all four Highmark service areas (Delaware, New York, Pennsylvania, and West Virginia). A grievance may likewise be filed up to 180 days after the original determination, and appeals can be filed by telephone or in writing.

1. Request the written denial letter that names the specific policy clause (J-1388, J-1389, or the J-0184 transition policy) your submission failed to satisfy.
2. For commercial members, Highmark also offers a physician peer-to-peer review before or at the point of denial — use it to resolve documentation gaps before filing a formal appeal.
3. File the internal appeal within 180 days, addressing the specific clause named in the denial letter (BMI threshold, comorbidity documentation, the 6-month diet/activity record, the type-2-diabetes attestation, or the ≥ 7.5% reauthorization weight-loss calculation).
4. Pennsylvania CHIP/Healthy Kids members have a shorter 60-day appeal window — do not assume the standard 180-day window applies.
5. If the internal appeal is denied, members may request an external independent review. Call the Member Service number on the ID card, or follow the appeal instructions printed in the denial letter.

Further reading

• Aetna GLP-1 prior authorization guide — how a different national payer structures its PA bulletins by drug.
• Best semaglutide providers — vetted cash-pay telehealth options if your Highmark plan excludes the anti-obesity benefit.
• Best tirzepatide providers — cash-pay options for members whose plan requires a Zepbound step they can't clear.